For the Evry, France-based company, the grant will support its vision of making its technology available as a platform for running oncology assays.
The funding will be used to run a study of breath-based biomarkers and measures of small airway function to enable the definitive diagnosis of asthma.
The Army previously awarded Abbott $11.3 million to develop a TBI test. Abbott has worked with DoD since 2014 to develop tests to help evaluate potential concussions.
The Polish company recently received 9 million Polish złoty ($2.4 million) from the country's National Center for Research and Development to support its activities.
The firm said that it will use the Horizon 2020 Phase II grant to fund a multicenter trial aimed at validating its platform for early detection of recurrent renal cell carcinoma.
Researchers at the University of Birmingham in the UK were awarded £275,000 to develop the new test to measure PSA levels better than conventional tests.
Led by investigators at the University of Trento in Italy, the team received a five-year, £5 million ($6.4 million) award recently to advance its work.
Relying on artificial intelligence, the company has crafted a software tool to assist pathologists in diagnosing cancers and delivering clinical reports.
Its first assay for complete blood counting employs lens-free imaging and a platform that uses a silicon chip to execute operations at the microscale level.
The company will receive an upfront $9.3 million to fund a clinical trial for its NGP phenotyping platform and is eligible for an additional $36 million.